SNN - Smith & Nephew plc
39.11 0.00 (0.00%)
After hours: 4:02PM EDT
| Previous Close | 38.75 |
| Open | 39.15 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 38.97 - 39.22 |
| 52 Week Range | 33.03 - 40.43 |
| Volume | 463,098 |
| Avg. Volume | 872,085 |
| Market Cap | 16.875B |
| Beta | 0.34 |
| PE Ratio (TTM) | 22.30 |
| EPS (TTM) | 1.75 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.70 (1.83%) |
| Ex-Dividend Date | 2018-04-05 |
| 1y Target Est | 42.90 |
- Simply Wall St.•13 hours ago
Does Smith & Nephew plc’s (LON:SN.) PE Ratio Warrant A Buy?
Smith & Nephew plc (LSE:SN.) trades with a trailing P/E of 21.7x, which is lower than the industry average of 29.6x. While this makes SN. appear like a great stockRead More...
- Simply Wall St.•10 days ago
Smith & Nephew plc (LON:SN.) Delivered A Better ROE Than The Industry, Here’s Why
Smith & Nephew plc (LSE:SN.) delivered an ROE of 16.52% over the past 12 months, which is an impressive feat relative to its industry average of 10.23% during the sameRead More...
- The Wall Street Journal•10 days ago
[$$] WPP Chairman Looks to Fill the Gap Left by Sorrell’s Sudden Exit
A little known private-equity executive will steer WPP PLC through one of its stormiest periods following the resignation last weekend of Martin Sorrell.
- American City Business Journals•23 days ago
Former Alere CEO named to head another medical device giant
One of Massachusetts’ largest medical device employers, London-based Smith & Nephew, has named a new CEO who’ll be familiar to that company’s 1,100 Massachusetts employees.
- Reuters•23 days ago
Smith & Nephew picks new CEO who sold his last company
Artificial hip and knee maker Smith & Nephew (SN.L), a perennial target of takeover speculation, said on Wednesday it had appointed a new chief executive with a track record of deal-making. Namal Nawana, who will replace Olivier Bohuon as CEO of the British company next month, most recently headed medical diagnostics firm Alere, where he oversaw its $5.3 billion sale to Abbott (ABT.N) in 2017. The medical technology firm, which also has wound-care and sports medicine units, is under pressure to improve margins and find new sources of growth as it competes with bigger rivals.
- Zacks•last month
Smith & Nephew (SNN): Moving Average Crossover Alert
Smith & Nephew plc (SNN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
- American City Business Journals•last month
Manufacturing company adding 100 jobs in Fort Worth in $29M expansion
Medical equipment supplier Smith & Nephew Inc. has selected its Fort Worth facility to locate a $29 million project, creating 100 new jobs. Fort Worth beat out at least three other cities for the project.
- PR Newswire•last month
Smith & Nephew Supports AAFAO Courses with Donation of More Than $3M of Equipment to The Podiatry Institute
LSE:SN), the global medical technology business, today announces the donation of more than $3M of trauma plates and screws, external fixation implants and instruments to The Podiatry Institute (PI). This equipment will be used to support ongoing educational courses conducted at the PI through the American Academy of Foot and Ankle Osteosynthesis (AAFAO). Smith & Nephew has been the sole sponsor of the comprehensive and advanced educational courses conducted by the PI and AAFAO for the past four years, contributing to resident education for nearly 1600 participants.
- Simply Wall St.•last month
Does Smith & Nephew plc’s (LON:SN.) -2.17% Earnings Drop Reflect A Longer Term Trend?
Measuring Smith & Nephew plc’s (LSE:SN.) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceedRead More...
- PR Newswire•2 months ago
IIROC Trade Resumption - SNN
VANCOUVER , March 7, 2018 /CNW/ - Trading resumes in: Company: Sunniva Inc. CSE Symbol: SNN Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension (halt) of trading in a security ...
- PR Newswire•2 months ago
IIROC Trading Halt - SNN
VANCOUVER , March 6, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Sunniva Inc. CSE Symbol: SNN Reason: At the request of the Company Pending News Halt Time (ET): 3:43 PM IIROC ...
- PR Newswire•2 months ago
New Q-FIX™ CURVED, Q-FIX MINI and SUTUREFIX CURVED All-Suture Anchor Systems help surgeons access challenging pathology while improving the quality of shoulder and hip repairs
LONDON , March 6, 2018 /PRNewswire/ -- Smith & Nephew (NYSE:SNN, LSE: SN), the global medical technology business, is pleased to announce the launch of Q-FIX ™ CURVED, Q-FIX MINI and SUTUREFIX CURVED ...
- PR Newswire•2 months ago
Smith & Nephew announces full commercial release of JOURNEY™ II XR Total Knee Arthroplasty
LONDON , March 6, 2018 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the full commercial release of bi-cruciate retaining JOURNEY II XR total ...
- Market Realist•2 months ago
Johnson & Johnson’s Acclarent Aera Balloon Dilation System
Acclarent received FDA approval for its Acclarent Aera Balloon Dilation System for the treatment of ETD (eustachian tube dysfunction) in September 2016. For details, read Inside Johnson & Johnson’s Latest US Medical Device Launch. On February 27, 2018, Johnson & Johnson’s subsidiary Acclarent announced that the company received FDA approval for the expanded indication for Acclarent Aera.
- Zacks•2 months ago
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Covidien and Smith & Nephew, Abbott Labs and Boston Scientific
Market Realist•2 months agoHow JNJ’s Orthopedic Medical Devices Performed in 4Q17 and 2017
How Johnson & Johnson's Medical Devices Business Fared in 2017
- Business Wire•2 months ago
Smith & Nephew: RCT demonstrates a 71% reduction in the onset of sacral pressure ulcers when adding ALLEVYN◊ LIFE to standard preventative protocol
Smith & Nephew plc , the global medical technology business, today announces the publication of a randomised controlled trial demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew’s leading multi-layer silicone adhesive foam dressing, to a standard care protocol significantly reduces the onset of pressure ulcers by 71% in elderly patients admitted to hospital for hip fracture1.
- Simply Wall St.•3 months ago
Does Smith & Nephew plc (LON:SN.) Have A Place In Your Dividend Portfolio?
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. In the past 10 years Smith & Nephew plc (LSE:SN.)Read More...
- PR Newswire•3 months ago
Smith & Nephew's Episode of Care Assurance Program (eCAP) reduces hospital readmission following total joint replacement surgery
LONDON , Jan. 18, 2018 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces results showing a near 75% decrease in readmission rates for joint arthroplasties ...
- Simply Wall St.•3 months ago
Is Smith & Nephew plc’s (LON:SN.) Balance Sheet Strong Enough To Weather A Storm?
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Smith & Nephew plc (LSE:SN.) a safer option. Risk-averse investors who are attracted to diversifiedRead More...
- Simply Wall St.•4 months ago
Is Smith & Nephew plc (LON:SN.) A Buy At Its Current PE Ratio?
Smith & Nephew plc (LSE:SN.) is trading with a trailing P/E of 17.5x, which is lower than the industry average of 31.3x. While this makes SN. appear like a greatRead More...
